Time slot's time in Taipei (GMT+8)
2025/11/21 14:00-17:30 Room 201 ABC
- Kick-on Seminar VII
Artificial Intelligence (AI): The Roadmap for Precision Medicine and Individualized Management
- Time
- Topic
- Speaker
- Moderator
- 14:30-15:00
- Large Language Models in Medicine: Benefits and Challenges
- Speaker:
Sheng-Fu Liang
(Taiwan)
- Moderator:
Kai-Cheng Hsu
(Taiwan)
- Kai-Cheng Hsu
- MD, PhD
-
President, Acer Medical
E-mail：edward.hsu@acer-medical.com
Executive Summary：
Dr. Kai-Cheng Hsu is a board-certified neurologist specializing in dementia, stroke, and sleep disorders. He received his M.D. from National Taiwan University and holds a Ph.D. in Chemical Engineering and an M.S. in Electrical Engineering from National Chung Cheng University.
From 2018 to 2020, he was a research fellow at the National Institute of Neurological Disorders and Stroke (NINDS), NIH, where he focused on AI and bioinformatics for neurological disorders.
He later served as Director of the AI Center at China Medical University Hospital (2020–2023), leading the development of AI tools integrated into clinical practice and approved by the Taiwan FDA.
In 2024, Dr. Hsu joined the Industrial Technology Research Institute (ITRI) to advance AI research in medical imaging, biomedical signals, and EHRs. Since April 2025, he has been President and Chief Medical Officer of Acer Medical, driving the clinical adoption and industrialization of AI-powered healthcare solutions.
Dr. Hsu’s work has been widely published in peer-reviewed journals and reflects his commitment to bridging medicine and engineering to improve patient care.
Dr. Kai-Cheng Hsu is a board-certified neurologist specializing in dementia, stroke, and sleep disorders. He received his M.D. from National Taiwan University and holds a Ph.D. in Chemical Engineering and an M.S. in Electrical Engineering from National Chung Cheng University.
From 2018 to 2020, he was a research fellow at the National Institute of Neurological Disorders and Stroke (NINDS), NIH, where he focused on AI and bioinformatics for neurological disorders.
He later served as Director of the AI Center at China Medical University Hospital (2020–2023), leading the development of AI tools integrated into clinical practice and approved by the Taiwan FDA.
In 2024, Dr. Hsu joined the Industrial Technology Research Institute (ITRI) to advance AI research in medical imaging, biomedical signals, and EHRs. Since April 2025, he has been President and Chief Medical Officer of Acer Medical, driving the clinical adoption and industrialization of AI-powered healthcare solutions.
Dr. Hsu’s work has been widely published in peer-reviewed journals and reflects his commitment to bridging medicine and engineering to improve patient care.
